85TiPA phase I trial of the safety and pharmacokinetics of cemiplimab, a human monoclonal antibody to programmed death-1, in Japanese patients with advanced malignancies, including expansion cohorts for patients with non-small-cell lung cancer
Annals of Oncology(2018)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要